The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2019 | SABR improves outcomes for stage 1 lung cancer
Iain Phillips
• 24 Jan 2019
Iain Phillips, MBBS, BSc, MSc, MRCP, FRCR, of NHS Lothian, Edinburgh, UK, discusses his group’s work on investigating outcomes after stereotactic ablative body radiotherapy (SABR) for stage 1 lung cancer from the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland. Dr Phillips highlights the benefits of SABR compared to standard radiotherapy.
